Becton Dickinson Files 2024 10-K
Ticker: BDX · Form: 10-K · Filed: Nov 27, 2024 · CIK: 10795
| Field | Detail |
|---|---|
| Company | Becton Dickinson & CO (BDX) |
| Form Type | 10-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $1.00 B, $3.911 billion, $1.548 billion, $268 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, healthcare
TL;DR
BDX 2024 10-K is in! Full financials and biz details out.
AI Summary
Becton Dickinson & Co. (BDX) filed its 10-K for the fiscal year ending September 30, 2024. The company, headquartered in Franklin Lakes, NJ, operates in the surgical and medical instruments sector. Key financial details and operational segments are outlined in the filing, which also includes information on various financial instruments and liabilities.
Why It Matters
This filing provides investors and analysts with a comprehensive overview of Becton Dickinson's financial performance, strategic positioning, and risk factors for the fiscal year 2024.
Risk Assessment
Risk Level: low — This is a standard annual financial filing (10-K) for a large, established public company, not indicating any immediate or unusual risks.
Key Numbers
- 0930 — Fiscal Year End (The filing covers the fiscal year ending on this date.)
- 20240930 — Period of Report (The reporting period for this 10-K filing.)
- 20241127 — Filing Date (The date the 10-K was officially filed with the SEC.)
Key Players & Entities
- BECTON DICKINSON & CO (company) — Filer
- FRANKLIN LAKES, NJ (location) — Company Headquarters
- 2018476800 (phone_number) — Business Phone
- 0930 (date) — Fiscal Year End
- 20240930 (date) — Period of Report
FAQ
What is Becton Dickinson & Co.'s primary industry?
Becton Dickinson & Co. is in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry, SIC code 3841.
Where is Becton Dickinson & Co. headquartered?
The company's business address is One Becton Dr, Franklin Lakes, NJ 07417-1880.
What is the SEC file number for Becton Dickinson & Co.?
The SEC file number is 001-04802.
What is the fiscal year end for Becton Dickinson & Co.?
The fiscal year end is September 30 (0930).
What is the accession number for this 10-K filing?
The accession number for this filing is 0000010795-24-000084.
Filing Stats: 4,214 words · 17 min read · ~14 pages · Grade level 16.7 · Accepted 2024-11-27 13:36:08
Key Financial Figures
- $1.00 B — ich Registered Common stock, par value $1.00 BDX New York Stock Exchange 1.900% Notes
- $3.911 billion — in connection with the acquisition was $3.911 billion. Since the acquisition date, financial
- $1.548 billion — in connection with the acquisition was $1.548 billion. Since the acquisition date, financial
- $268 m — e-tax gain on the sale of approximately $268 million, which was recorded as a componen
Filing Documents
- bdx-20240930.htm (10-K) — 2963KB
- exhibit4ccdescriptionofsec.htm (EX-4.CC) — 173KB
- exhibit10dbd-dcp2024restat.htm (EX-10.D) — 496KB
- exhibit10jicompiledbecton-.htm (EX-10.JI) — 139KB
- exhibit19globalinsidertrad.htm (EX-19) — 76KB
- exhibit21fy24q4formforwdesk.htm (EX-21) — 165KB
- a09-30x2024ex22.htm (EX-22) — 3KB
- a09-30x2024ex23.htm (EX-23) — 3KB
- a09-30x2024ex31.htm (EX-31) — 15KB
- a09-30x2024ex32.htm (EX-32) — 7KB
- exhibit97bectondickinson-p.htm (EX-97) — 25KB
- screenshot2024-11x21140915a.jpg (GRAPHIC) — 172KB
- 0000010795-24-000084.txt ( ) — 17203KB
- bdx-20240930.xsd (EX-101.SCH) — 95KB
- bdx-20240930_cal.xml (EX-101.CAL) — 126KB
- bdx-20240930_def.xml (EX-101.DEF) — 490KB
- bdx-20240930_lab.xml (EX-101.LAB) — 1116KB
- bdx-20240930_pre.xml (EX-101.PRE) — 804KB
- bdx-20240930_htm.xml (XML) — 3093KB
Risk Factors
Item 1A. Risk Factors 13 Information About Our Executive Officers 27
Unresolved Staff Comments
Item 1B. Unresolved Staff Comments 28
Cybersecurity
Item 1C. Cybersecurity 28
Properties
Item 2. Properties 30
Legal Proceedings
Item 3. Legal Proceedings 31
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 31 PART II 32
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 32
(Reserved)
Item 6. (Reserved) 32
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 33
Quantitative and Qualitative Disclosures About Market Risk
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 57
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data 58
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 113
Controls and Procedures
Item 9A. Controls and Procedures 113
Other Information
Item 9B. Other Information 113
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 114 PART III 115
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance 115
Executive Compensation
Item 11. Executive Compensation 115
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 115
Certain Relationships and Related Transactions, and Director Independence
Item 13. Certain Relationships and Related Transactions, and Director Independence 115
Principal Accounting Fees and Services
Item 14. Principal Accounting Fees and Services 115 PART IV 116
Exhibits, Financial Statement Schedules
Item 15. Exhibits, Financial Statement Schedules 116
Form 10-K Summary
Item 16. Form 10-K Summary 116 EXHIBIT INDEX 117
SIGNATURES
SIGNATURES 123 Table of Contents PART I
Business
Item 1. Business. General Becton, Dickinson and Company (also referred to herein as "BD") was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD's executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to "BD", "the Company", "we", "our" or "us" refer to Becton, Dickinson and Company and its domestic and foreign subsidiaries, unless otherwise indicated by the context. BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications. Business Segments BD's operations consist of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. As is further described below, on September 3, 2024, BD completed its acquisition of Edwards Lifesciences' Critical Care product group ("Critical Care"), which was renamed as BD Advanced Patient Monitoring ("Advanced Patient Monitoring") and operates as a separate organizational unit within the Company's Medical segment. Information with respect to BD's business segments is included in Notes 8, 11 and 16, respectively, to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference. BD Medical BD Medical produces a broad array